Close Menu

Cepheid

Cepheid and the University of Medicine and Dentistry of New Jersey will work on developing a 10-color detection technology for the firm's GeneXpert System.

The GWDN Index of 36 molecular biology tools and molecular diagnostics makers gained ground for the second month in a row, with Affymetrix rising significantly during that time period. Sequenom's tumble occurred on the final day of the month.

The test simultaneously identifies Mycobacterium tuberculosis and resistance to first-line drug therapy rifampicin.

Cepheid's new assay is the 10th Xpert molecular test to receive the CE-IVD Mark.

Mari Baker is leaving Navigenics, Andrew von Eschenbach has joined a consulting firm, Jay Flatley takes a seat on Helixis' board, and more.

The molecular diagnostics firm's decline in sales to clinical partners and biothreat customers was the primary cause of its expected decrease in Q4 revenues. It also announced a series of measures aimed at reining in costs in 2009.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.